Switching From Docetaxel to Paclitaxel and Bevacizumab in NSCLC

Share this content:
Allowing patients with non-squamous non-small cell lung cancer to cross over demonstrated a progression-free survival benefit.
Allowing patients with non-squamous non-small cell lung cancer to cross over demonstrated a progression-free survival benefit.

Allowing patients with non-squamous non-small cell lung cancer (NSCLC) to cross over from a study arm in which they received weekly docetaxel to 1 in which they received weekly paclitaxel and bevacizumab demonstrated a progression-free survival (PFS) benefit, according to results presented at the International Association for the Study of Lung Cancer (IASLC) 17th Annual World Conference on Lung Cancer in Austria.1

The phase 3 ULTIMATE (ClinicalTrials.gov Identifier: NCT01763671) clinical trial compared docetaxel (Arm A) to paclitaxel plus bevacizumab, an angiogenesis inhibitor (Arm B), as second- and third-line therapy for patients with non-squamous NSCLC. At progression, patients were given the option to cross from 1 study arm to the other. Patients who did not cross over received a post-discontinuation treatment within 60 days of progression. PFS and overall survival (OS) were calculated from day 1 of post-discontinuation treatment.

PFS was significantly improved in Arm B (5.4 months vs 3.9 months in Arm A). Of the patients in Arm A (55), those who crossed over to Arm B (21, 38.2%) had a median PFS of 4.9 months and a median OS of 12.5 months post-discontinuation. Those who did not cross over, but received a post-discontinuation treatment, had a median PFS of 1.7 months and OS of 4.1 months post-discontinuation.

RELATED: Multiple Genomic Mutations in Nearly 1% of Patients With NSCLC

Of the patients in Arm B (111), those who crossed over to Arm A (9, 8.3%), median PFS was 1.9 months post-discontinuation. Those who did not cross over, but received a post-discontinuation treatment, had a median PFS of 1.9 months and median OS of 5.0 months post-discontinuation.

Reference

  1. Cortot AB, Audigier Valette C, Molinier O, et al. Prolonged OS of patients exposed to weekly paclitaxel and bevacizumab: impact of the cross-over in the IFCT-1103 ULTIMATE study. Paper presented at: International Association for the Study of Lung Cancer 17th World Conference on Lung Cancer; December 2016; Vienna, Austria. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs